The growing development effort into evaluating RNA as a target for novel therapeutics could lead to a novel type of therapy to treat heart failure, according to the clinical-stage German biotech, Cardior Pharmaceuticals GmbH.
Cardior has started a Phase Ib clinical study with its lead compound, CDR132L, an antisense oligonucleotide that inhibits a non-coding...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?